United States Patent 7,301,050: Claim Scope, Patent Strength, Exclusivity and Competitive Landscape

U.S. Patent No. 7,301,050 covers a broad genus of substituted phenoxyacetic-acid compounds, narrower species, pharmaceutical compositions, and stereoisomeric compounds. The claims are directed to small-molecule therapeutic candidates rather than a clearly identifiable FDA-approved active ingredient. The central chemical architecture contains a substituted aromatic acid linked through sulfur or oxygen-containing side chains to a second substituted aromatic or heteroaromatic region.

The patent’s commercial value depends on whether a marketed product falls within claim 1 or the narrower species claims 47 through 54. The claims alone do not establish an approved drug, Orange Book listing, active exclusivity period, patent-term adjustment, patent-term extension, or litigation outcome.

What compounds does U.S. Patent 7,301,050 protect?

The patent protects compounds represented by Formula (I), together with pharmaceutically acceptable salts. Claim 1 is the principal genus claim. It defines a large chemical family through variables X, Y, Z, W, R1 through R6, and n.

The principal structural elements are:

Claim element	Scope
X	Covalent bond, sulfur, or oxygen
Y	Sulfur or oxygen
Z	Oxygen, CH, or CH2, with Z restricted to oxygen when Y is oxygen
W	Saturated, unsaturated, or partially unsaturated carbon chains
R1 and R2	Hydrogen, C1-C3 alkyl, C1-C3 alkoxy, halogen, or dialkylamino substituents
R3 and R4	Hydrogen, halogen, cyano, hydroxy, acetyl, alkyl, alkoxy, or dialkylamino substituents
R5	Broad alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and ether-containing groups
R6	Hydrogen or absent, depending on the W configuration
n	1 or 2
Salt form	Pharmaceutically acceptable salt

Claim 1 is drafted as a Markush claim. Each variable includes multiple alternatives, producing a potentially very large number of individual compounds. The claim does not protect every compound having a phenoxyacetic-acid group. Infringement requires a product to satisfy every limitation of the selected claim construction, including the specific X, Y, Z, W, substituent, stereochemical, and ring-attachment requirements.

How broad is claim 1?

Claim 1 has substantial formal breadth but several structural limitations constrain its practical reach.

The claim covers:

Sulfur-linked compounds.
Oxygen-linked compounds.
Carbon-linked analogues where X is a covalent bond.
Saturated and unsaturated side chains.
One- and two-carbon ring-linking configurations.
Multiple substitution patterns on both aromatic regions.
Neutral compounds and pharmaceutically acceptable salts.

The broadest commercial subfamilies appear to be the sulfur-containing phenoxyacetic acids with an ether-linked trifluoromethylphenyl group. The examples repeatedly identify structures containing:

A 2-methyl-substituted phenoxyacetic-acid ring.
A sulfur atom connecting that ring to a substituted propyl or butyl chain.
A 4-trifluoromethylphenoxy substituent.
An ether, alkoxy, alkene, or related substituent on the side chain.
R or S stereochemistry at the side-chain carbon.

The specification would control the interpretation of the structural shorthand and chemical nomenclature. The supplied claim text is not sufficient by itself to determine the complete three-dimensional structure represented by Formula (I).

Which claims are the most commercially important?

Claims 47 through 54 are the principal species claims. They identify specific compounds or limited groups of compounds rather than only broad substituent classes.

Claims 47 through 50

These claims cover the unsubstituted, racemic, and enantiomeric forms of:

{4-[2-Ethoxy-3-(4-trifluoromethyl-phenoxy)-propylsulfanyl]-2-methyl-phenoxy}-acetic acid
The corresponding R enantiomer
The corresponding S enantiomer

Claims 48, 49, and 50 separately claim the racemate and each enantiomer. This structure is likely the most important species in the patent because it is expressly identified in several dependent claims and is representative of the recurring scaffold.

Claims 51 through 53

These claims cover additional analogues, including:

Butyl and pentyl derivatives.
Cyano-substituted derivatives.
Allyloxy and methoxymethoxy analogues.
Phenyl and phenoxy substitutions.
Thiophene-containing analogues.
Alkene-containing derivatives.
Methoxy and ethoxy side-chain variants.
Cyclized dihydropyran-containing compounds.

Claim 54

Claim 54 focuses on R-configured compounds and includes:

Trifluoromethoxyphenoxy analogues.
4-chlorophenoxy and 4-tert-butylphenoxy analogues.
Phenylsulfanyl-acetic-acid variants.
R-configured butyl and propyl derivatives.

These claims provide a narrower fallback position if the broad genus claim is challenged for lack of novelty, written description, enablement, or obviousness.

What does claim 55 protect?

Claim 55 covers a pharmaceutical composition comprising a compound within specified claims, including claims 1, 27, 30 through 32, 34, 36 through 40, 42, 44 through 47, and 51 through 54.

This is a composition claim, not a method-of-treatment claim. It does not expressly recite:

A therapeutic indication.
A dosage amount.
A route of administration.
A formulation type.
A pharmaceutically acceptable carrier.
A sustained-release or controlled-release system.
A specific patient population.

As a result, claim 55 may provide composition-level coverage, but its commercial strength depends on the compound definition incorporated from the referenced claims and on the patent’s validity and enforceability.

What formulations are protected?

The supplied claims do not contain a detailed formulation platform. Claim 55 broadly covers a pharmaceutical composition comprising a claimed compound, but it does not separately claim:

Tablets.
Capsules.
Injectable formulations.
Oral solutions.
Solid dispersions.
Nanoparticles.
Liposomes.
Depot formulations.
Controlled-release matrices.
Specific excipient combinations.

The patent therefore appears stronger as a compound patent than as a formulation patent. A later-developed dosage form could require a separate formulation patent if it adds a non-obvious composition, release profile, solid form, polymorph, salt, or manufacturing process.

Do the claims cover methods of treatment?

No express method-of-treatment claim appears in the supplied claim set. The claims are directed to compounds and compositions.

This distinction matters. A company could potentially avoid direct infringement of a composition claim through a non-infringing compound, but method-of-use protection would require separate claims directed to administering the compound for a defined condition. The supplied claim set does not independently protect a disease indication, biomarker-defined population, dosage regimen, or combination therapy.

What chemical features create the primary infringement risk?

The highest-risk design-around area is the recurring aromatic thioether and phenoxyacetic-acid arrangement.

A product is most likely to face literal infringement risk if it contains:

A phenoxyacetic-acid or phenylsulfanyl-acetic-acid region.
A para sulfur-linked side chain.
A 2-methyl-substituted aromatic ring.
A propyl or butyl linker.
A 4-trifluoromethylphenoxy or 4-trifluoromethoxyphenoxy group.
An ethoxy, methoxy, allyloxy, or related substituent.
The claimed R or S configuration where required.

Potential design-around strategies include changing:

The sulfur linkage to carbon or oxygen.
The substitution position on either aromatic ring.
The trifluoromethyl group.
The acid group.
The side-chain length.
The stereochemical configuration.
The saturation state of the linker.
The ring system connected through X, Y, or Z.

These changes require a full claim chart. A single structural modification may avoid literal infringement but still raise a doctrine-of-equivalents issue, depending on prosecution history and the function-way-result analysis.

How strong is the patent estate?

Strengths

The estate has several strengths:

Claim 1 covers a large chemical genus.
Claims 47 through 54 provide specific species fallback positions.
Claims separately address racemates and enantiomers.
The claims cover sulfur, oxygen, and carbon-linked variants.
The composition claim can support commercial pharmaceutical products containing claimed compounds.
The repeated exemplification of the trifluoromethylphenoxy scaffold may improve the practical relevance of the species claims.

Weaknesses

The primary vulnerabilities are:

The breadth of claim 1 may create written-description and enablement challenges.
The extensive Markush definitions may invite obviousness attacks based on prior PPAR-ligand or phenoxyacetic-acid chemistry.
The supplied text contains apparent typographical or transcription problems.
Some dependent claims appear internally awkward or redundant.
The claims do not expressly recite a method of treatment.
The composition claim lacks detailed formulation limitations.
Commercial value is limited if no marketed product falls within the claimed genus.

Several apparent drafting issues deserve review against the issued patent:

Claim	Apparent issue
18	“CH” appears in a substituent list where “CH3” may have been intended
44	The claim does not clearly restate all variables, including R6
55	The phrase “any of claim 1, 27...” is grammatically irregular
56	“C1-5-C1-5alkoxy” appears to be a typographical defect
47-54	Chemical names contain inconsistent spacing and transcription artifacts

The issued patent, file history, certificate of correction, and prosecution amendments control. The supplied claim text should not be used as the sole litigation claim construction record.

When does U.S. Patent 7,301,050 lose exclusivity?

The claims do not contain the filing date, earliest priority date, patent-term adjustment, terminal disclaimer, or patent-term extension. Under U.S. law, the ordinary term for a utility patent is generally 20 years from the earliest effective nonprovisional filing date, subject to applicable adjustments and disclaimers.[2]

A reliable expiration analysis therefore requires the patent’s continuity data and USPTO term information. The grant date of November 27, 2007 does not determine the expiration date. Patent No. 7,301,050 is an early-2000s patent and its ordinary term would generally fall in the early 2020s, subject to the statutory term calculation.

No patent-term extension can be inferred from the claims. Patent-term extension under 35 U.S.C. § 156 depends on an approved product, regulatory review period, and statutory eligibility. The claim set does not identify an approved active ingredient or regulatory product.

What is the Orange Book status?

The supplied record does not identify an FDA-approved product, proprietary name, applicant, NDA, or active ingredient associated with U.S. Patent 7,301,050.

An Orange Book listing requires an approved drug application and an FDA-submitted patent claim associated with the approved product. A compound patent may exist without appearing in the Orange Book if:

The compound was never approved.
The patent holder did not submit it for listing.
The patent does not claim the approved drug or an approved method of use.
The product is not subject to an NDA listing relevant to the patent.

The patent number alone is therefore insufficient to establish Orange Book status.[3]

Are Paragraph IV challenges relevant?

Paragraph IV litigation is relevant only if an ANDA applicant challenges an Orange Book-listed patent for an approved reference listed drug. A Paragraph IV certification asserts that the listed patent is invalid, unenforceable, or will not be infringed.[4]

No Paragraph IV challenge, ANDA litigation, settlement, or 30-month stay can be established from the supplied claims. If no approved product is associated with the patent, there would be no ordinary Orange Book-based Paragraph IV pathway tied to this patent.

For a future generic product, the risk analysis would depend on:

Whether the reference drug is approved.
Whether 7,301,050 is listed.
Whether the generic contains a compound within a live claim.
Whether the patent term has expired.
Whether other patents cover salts, polymorphs, formulations, methods of use, or manufacturing processes.

Does biosimilar risk apply?

No. Biosimilar rules apply to biological products, while the claims in Patent 7,301,050 cover small molecules and pharmaceutical compositions containing them.

The relevant competitive threat would be a generic or alternative small molecule, not a biosimilar. If a claimed compound had been approved, an ANDA or 505(b)(2) pathway could be more relevant than a biosimilar application.[5]

What patent litigation and settlement agreements affect the patent?

No litigation, settlement agreement, consent judgment, terminal disclaimer, reexamination certificate, or post-grant cancellation is identified in the supplied material.

A complete litigation assessment would require review of PACER, USPTO Patent Examination Data System records, Patent Center, and relevant district-court or Federal Circuit decisions. The claims alone do not establish whether the patent was asserted, invalidated, narrowed, licensed, or abandoned.

What licensing or commercial deals are associated with the patent?

No licensing agreement, assignment, merger transaction, or commercialization deal is identified in the supplied claims.

The patent appears to cover research-stage medicinal chemistry subject matter. The presence of broad genus claims and numerous enumerated analogues does not establish that the patent owner commercialized a drug or licensed the technology. Patent ownership, assignment history, and licensing rights must be distinguished from the original named inventor or applicant.

How does this patent compare with a typical drug patent estate?

Estate component	U.S. 7,301,050 based on supplied claims	Typical marketed-drug estate
Core compound claim	Yes	Usually yes
Specific species claims	Yes	Usually yes
Enantiomer claims	Yes	Often
Composition claim	Yes, broad	Usually yes
Formulation claims	Not apparent	Often
Method-of-use claims	Not apparent	Usually
Salt or polymorph claims	Not apparent	Often
Manufacturing claims	Not apparent	Sometimes
Orange Book relevance	Not established	Product-dependent
Biosimilar relevance	No	Biologic-dependent
Generic litigation risk	Product-dependent	Often material

The patent is structurally stronger as a compound/genus patent than as a complete life-cycle estate. A commercial product would likely require additional protection for formulation, solid state, dosing, treatment method, manufacturing, and potentially combination therapy.

What generic launch scenarios exist?

Three scenarios are possible:

If no approved drug is tied to the patent, the patent may have no direct ANDA blocking function.
If a product is covered and the patent is expired, a generic could launch subject to other live patents and regulatory requirements.
If a product is covered and related patents remain active, an ANDA applicant could pursue a Paragraph IV challenge, a section viii carve-out where available, or a later launch after expiration.

A generic company would need to map the proposed active ingredient against claim 1 and the narrower species claims. It would also need to examine salts, stereochemistry, impurities, intermediates, formulation, and manufacturing steps.

Key Takeaways

U.S. Patent 7,301,050 claims a broad genus of substituted phenoxyacetic-acid compounds and pharmaceutically acceptable salts.
Claims 47 through 54 provide narrower species protection, including racemic and R/S forms.
The recurring commercial scaffold contains a phenoxyacetic-acid group, sulfur-linked side chain, and trifluoromethylphenoxy substituent.
Claim 55 provides broad pharmaceutical-composition protection but does not present a detailed formulation platform.
No express method-of-treatment, dosage-regimen, polymorph, salt-specific, or manufacturing claims appear in the supplied claims.
The patent is a small-molecule patent, so biosimilar analysis does not apply.
Orange Book status, Paragraph IV activity, litigation, settlements, licensing, and exact expiration require records beyond the claim text.
The patent’s strongest practical value would arise if a marketed product were structurally within the specific compounds claimed in claims 47 through 54.
A complete freedom-to-operate analysis must include prosecution history, continuity data, term information, assignments, related patents, and any issued corrections.

FAQs

Is U.S. Patent 7,301,050 a patent for GW501516?

The supplied claims do not identify GW501516 by name. The expressly claimed structures are substituted phenoxyacetic-acid compounds with sulfur- or oxygen-containing linkers. Chemical identity must be confirmed by comparing the exact structure of the candidate product with the issued claims.

Can a company avoid this patent by replacing sulfur with oxygen?

Potentially, but not automatically. Claim 1 expressly includes both sulfur and oxygen in certain positions. Replacing sulfur with oxygen avoids infringement only if the resulting compound falls outside every asserted claim and is not captured under an equivalent claim construction.

Does the patent cover both R and S enantiomers?

Yes. Claims 47, 49, and 50 expressly identify racemic and R/S compounds for one principal species. Claim 54 separately identifies multiple R-configured analogues.

Does the patent protect a tablet containing a claimed compound?

Claim 55 broadly covers a pharmaceutical composition comprising specified claimed compounds. It does not expressly require a tablet, capsule, particular excipient, or release profile.

Can a generic applicant file a Paragraph IV certification against this patent?

Only if the patent is listed in the Orange Book for an approved reference drug and remains relevant under the applicable Hatch-Waxman framework. The claim text alone does not establish those conditions.

References

United States Patent No. 7,301,050, claims 1-58 (2007).
35 U.S.C. §§ 154, 156 (2024).
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
21 U.S.C. § 355(j)(2)(A)(vii)(IV); 35 U.S.C. § 271(e)(2).
U.S. Food and Drug Administration. (2024). Abbreviated new drug application pathway and 505(b)(2) applications.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Gilead Sciences Inc	LIVDELZI	seladelpar lysine	CAPSULE;ORAL	217899-001	Aug 14, 2024		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y	Y			⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	045773	⤷ Start Trial
Austria	E542793	⤷ Start Trial
Australia	2004285849	⤷ Start Trial
Brazil	PI0414268	⤷ Start Trial
Canada	2539446	⤷ Start Trial
China	1882533	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,301,050

Which drugs does patent 7,301,050 protect, and when does it expire?

Summary for Patent: 7,301,050